Blaze Bioscience publishes Phase-1 trial results of tozuleristide
Category: #health  By Pankaj Singh  Date: 2019-05-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Blaze Bioscience publishes Phase-1 trial results of tozuleristide

Exploratory studies with the Odyssey CLx (LI-COR Biosciences), FLUOBEAM®800 (Fluoptics), and SIRIS (Teal Light Surgical) imaging devices, were conducted.

The U.S. based biotechnology company Blaze Bioscience, Inc., has reportedly announced the publication of Phase 1 results in the peer-reviewed journal Neurosurgery. The publication has been entitled by Patil et al and is now available online in Neurosurgery Now!.

Reportedly, the data for publication has been reported from 17 subjects in dose-escalation, a single dose, open-label clinical trial organized at the NEWRO Foundation in Brisbane, Australia and Cedars-Sinai Medical Center in Los Angeles. The study had a primary objective to evaluate the tolerability and safety of tozuleristide in adult subjects with glioma undergoing surgery. Tozuleristide was detected to be well tolerated at all tested doses with no dose limiting toxicities observed. A maximum tolerated dose was not reached.

Exploratory studies with the Odyssey CLx (LI-COR Biosciences), FLUOBEAM®800 (Fluoptics), and SIRIS (Teal Light Surgical) imaging devices, were conducted. Fluorescence signal was observed in both low- and high-grade tumors. It was also visible post dosing from 3 to 27 hours.

Dr. Adam Mamelak, MD, Neurosurgeon, Cedars-Sinai and Senior Author on the publication, reportedly stated that Tozuleristide fluorescence envisaged with a high-resolution imaging system represents great promise as tool to expand extent of restriction for both low- and high- grade gliomas while preserving critical normal brain tissue. The single most vital factor for enhancing survival and quality of life in brain tumor patients is improved resection, he further added.

Mamelak reportedly noted that further clinical trials will be warranted based on the encouraging results from the recently concluded trial.

Dr. Dennis Miller, SVP of Development, Blaze Bioscience, reportedly stated that a way has been paved by the positive data in adult glioma subjects for our broader clinical trial of pediatric brain cancer. The study also indicated the need for improved imaging devices for application of brain cancer surgery which led to the development of the Canvas Imaging System, already in use in continuing pivotal study, he further added. 

 

Source credit: https://www.businesswire.com/news/home/20190509005235/en/Blaze-Bioscience-Announces-Publication-Phase-1-Clinical

https://www.apnews.com/Business%20Wire/f923853788b84dcdbdfd8b191d8334c5



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Zelegent expands to OSA therapeutics with MISH platform acquisition
Zelegent expands to OSA therapeutics with MISH platform acquisition
By Pankaj Singh

  • MISH Technology stands for Minimally Invasive Suspension of the Hyoid and is a novel pre-clinical product line meant to treat obstructive sleep apnea (OSA).
  • SunGen Pharma and Elite Pharmaceuticals file an ANDA with the FDA
    SunGen Pharma and Elite Pharmaceuticals file an ANDA with the FDA
    By Pankaj Singh

    This is the second ANDA filed by both the companies, giving Elite Pharmaceutical the exclusive right to retail the drug.

    Elite Pharmaceuticals, Inc. a pharmaceutica...

Ribon Therapeutics doses first patient in RBN-2397 Phase 1 trial
Ribon Therapeutics doses first patient in RBN-2397 Phase 1 trial
By Pankaj Singh

  • The Phase 1 clinical trial assessing RBN-2397 will be the first clinical evaluation of monoPARP Inhibitor.
     
  • RBN-2397 is the company&rs...